Company: LGN
Filing Date: 2025-11-03
Form Type: DRS
Source: 0001193125-25-262782
Chunk: 2

Company: Legence Corp.
Filing Date: 2025-11-03
Form: DRS
Chunk 2
---
 stockholders named in this prospectus are offering shares of Class A common stock, par value $0.01 per share (“Class A Common Stock”), to the underwriters in a firm commitment offering. We are not selling any shares of Class A Common Stock under this prospectus and will not receive any proceeds from the sale of shares in this offering by the selling stockholders. Prior to the consummation of this offering, one of the selling stockholders will exchange LGN Units for shares of our Class A Common Stock to be sold by it in the offering. See “Principal and Selling Stockholders” and “Certain Relationships and Related Party Transactions—Exchange Agreement.” Our Class A Common Stock is listed on the Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “LGN.” On , 2025, the last reported sale price of our Class A Common Stock on the Nasdaq was $ per share. Investing in our Class A Common Stock involves risks, including those described under “ Risk Factors” beginning on page 16 of this prospectus.

|                                                        |     | Per share |     | Total |
|:-------------------------------------------------------|:----|:----------|:----|:------|
| Price to the public                                    |     | $         |     | $     |
| Underwriting discounts and                             
 commissions(1)                                         |     | $         |     | $     |
| Proceeds to the selling stockholders (before expenses) |     | $         |     | $     |

| (1) | We refer you to “Underwriting” beginning on page 154 of this               
 prospectus for additional information regarding underwriting compensation. |

The selling stockholders (as defined below) have granted the underwriters the option for a period of 30 days after the date of this prospectus to purchase up to additional shares of Class A Common Stock on the same terms and conditions set forth above. Neither the Securities and Exchange Commission (the “SEC”) nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. The underwriters expect to deliver the shares on or about , 2025. Prospectus dated , 2025.

Confidential Treatment Requested by Legence Corp. Pursuant to 17 C.F.R. Section 200.83 TABLE OF CONTENTS

| Commonly Used Defined Terms                                                |     |  ii |
| Presentation of Financial and Operating Data                               |     |